spacer
home > pmps > winter 2019 > improving the chain’s efficiency
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Improving the Chain’s Efficiency

Falsified medicinal products represent one of the most significant challenges for patient safety and remains a key issue of public health. The Falsified Medicines Directive (FMD) 2011/62/EU will come into force on 9 February 2019. This new legislation aims to prevent counterfeit or unauthorised prescription medicine from entering the legal supply chain. Counterfeit medication costs the pharmaceutical industry billions of pounds every year, and, more importantly, it puts patients at risk. As such, serialisation is the key to ensuring that businesses become, and remain, compliant, keeping patient safety at the fore.

The Requirements

Firstly, knowing and understanding what the requirements of the Directive are is important. When looking at FMD in a broader sense, the requirements fall into five separate categories:

• An obligatory feature on the outer packaging of prescription medicines that demonstrates identification and enables product verification
• An obligatory feature on the outer packaging of prescription medicines to demonstrate that they have not been tampered with (an anti-tamper device)
• Strengthened requirements for the inspection of the manufacturers of APIs
• The obligation for manufacturers to report any suspicions of falsified medicines
• An obligatory logo to be applied to websites of legally operating online pharmacies, with a link to official national registers

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Christian Taylor is a GS1-accredited Business Consultant, specialising in serialisation and the FMD and unique device identifier legislation. With over 10 years’ experience delivering infrastructure and software solutions within industries including pharma, military, and government, Christian is one of the leading authorities in the ZetesAtlas solution in the UK and Europe.
spacer
Christian Taylor
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement